What exactly did BTIG change in its March 03, 2026 TBPH note?

BTIG maintained a **Buy** rating on Theravance Biopharma, Inc. (TBPH) on March 03, 2026, but cut its price target to **$21** after a trial miss. The firm kept conviction in long-term potential while acknowledging near-term clinical risk.

How should investors interpret the TBPH analyst rating change?

A maintained Buy with a lower PT signals continued analyst confidence in TBPH’s fundamentals but increased near-term uncertainty. Investors should reassess time horizons, monitor upcoming milestones, and consider position size relative to clinical risk.

Did the stock move significantly after the BTIG update?

The market reaction was muted, about **0.58% ($0.08)** on the update. That limited move suggests investors viewed the BTIG TBPH analyst rating update as an adjustment rather than a decisive negative event.

How does Meyka AI incorporate this change in its TBPH grade?

Meyka AI rates TBPH with a grade of B+. We factor in analyst moves like BTIG’s price target cut, sector performance, growth metrics, and benchmark comparisons. Grades inform but do not replace individual research.

Analyst Ratings

BTIG Maintains Buy on Theravance Biopharma, Inc. (TBPH) March 2026

ByDanny Kontos March 4, 2026

BTIG on March 03, 2026 maintained a Buy rating on Theravance Biopharma, Inc. (TBPH), a clear signal in the latest TBPH analyst rating news. The firm cut its price target to $21 after a clinical trial miss, keeping conviction in the stock but flagging near-term risk. Market reaction was muted, a 0.58% intraday move equal to $0.08. This note summarizes BTIG’s action, the price target change, and what the TBPH analyst rating means for investors.